Amarin Corp Plc (AMRN)

[ziploc_1]

KM has had previous experience with a combo drug with statin to treat CVD at Merck...

KM was able to reverse a sales decline in Merck's lipid lowering business with the launch of an LDL-lowering combo drug, Atozet....This was a Lipitor -Ezetimide combo...The doses of the combo drug were ...Lipitor 10-20-40-80 mgm. with Ezetimide 10 mgm....Amarin should give a high priority to producing a combo statin-EPA drug with the same doses of Lipitor as in Atozet ...together with a 40 gm once a day Vascepa...or, if necessary, a 20 gm twice a day Vascepa..

It would have te folllowing advantages...
--be more effective than Atozet in reducing CVD
--benefit from patent protection
--introduce more Docs and more patients to the benefits of Vascepa.
--